Respiratory Syncytial Virus Infection in Adults

Edward E Walsh

doi:10.1055/s-0031-1283282

Seminars in Respiratory and Critical Care Medicine, Table of Contents

Semin Respir Crit Care Med 2011; 32(4): 423-432
DOI: 10.1055/s-0031-1283282

Respiratory Syncytial Virus Infection in Adults

Edward E. Walsh¹ ^, ²

¹Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York
²Rochester General Hospital, Rochester, New York

Abstract

ABSTRACT

Respiratory syncytial virus (RSV), an enveloped RNA virus in the Paramyxovirus family, is the most important cause of lower respiratory tract infection in infants and young children, accounting for ~100,000 pediatric hospitalizations and 250 deaths annually in the United States. Despite primarily being recognized as a pediatric pathogen, RSV reinfection causes substantial disease in all adult populations, including healthy young persons, old and frail individuals, those with chronic obstructive pulmonary disease and immunocompromised patients. Most illnesses are mild in adults, but significant morbidity and mortality can develop. In contrast to infants, diagnosis of RSV infections is difficult due to low virus shedding, and optimal diagnosis requires molecular tests. Unfortunately, antiviral therapy is of limited benefit. Ribavirin and palivizumab are the only approved pharmacological agents for RSV treatment and prophylaxis, respectively, and are primarily used in infants; data regarding their usefulness in adults are limited. Currently, specific antiviral therapy is generally reserved for severely immunocompromised patients or severe respiratory failure. The greatest promise for reducing the impact of RSV in adults may be through immunization. However, an effective vaccine for RSV is not currently available.

KEYWORDS

Respiratory syncytial virus - RSV - palivizumab - respiratory viral infections

Full Text

References

REFERENCES

1 Blount Jr R E, Morris J A, Savage R E. Recovery of cytopathogenic agent from chimpanzees with coryza. Proc Soc Exp Biol Med. 1956; 92 (3) 544-549
2 Chanock R, Roizman B, Myers R. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). I. Isolation, properties and characterization. Am J Hyg. 1957; 66 (3) 281-290
3 Kim H W, Arrobio J O, Brandt C D et al.. Epidemiology of respiratory syncytial virus infection in Washington, D.C., I: Importance of the virus in different respiratory tract disease syndromes and temporal distribution of infection. Am J Epidemiol. 1973; 98 (3) 216-225
4 Parrott R H, Kim H W, Arrobio J O et al.. Epidemiology of respiratory syncytial virus infection in Washington, D.C., II: Infection and disease with respect to age, immunologic status, race and sex. Am J Epidemiol. 1973; 98 (4) 289-300
5 Brandt C D, Kim H W, Arrobio J O et al.. Epidemiology of respiratory syncytial virus infection in Washington, D.C., III: Composite analysis of eleven consecutive yearly epidemics. Am J Epidemiol. 1973; 98 (5) 355-364
6 Nokes D J, Okiro E A, Ngama M et al.. Respiratory syncytial virus epidemiology in a birth cohort from Kilifi district, Kenya: infection during the first year of life. J Infect Dis. 2004; 190 (10) 1828-1832
7 Nair H, Nokes D J, Gessner B D et al.. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010; 375 (9725) 1545-1555
8 Shay D K, Holman R C, Newman R D, Liu L L, Stout J W, Anderson L J. Bronchiolitis-associated hospitalizations among US children, 1980–1996. JAMA. 1999; 282 (15) 1440-1446
9 Zambon M C, Stockton J D, Clewley J P, Fleming D M. Contribution of influenza and respiratory syncytial virus to community cases of influenza-like illness: an observational study. Lancet. 2001; 358 (9291) 1410-1416
10 Falsey A R, Hennessey P A, Formica M A, Cox C, Walsh E E. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005; 352 (17) 1749-1759
11 Collins P L, Murphy B R. New generation live vaccines against human respiratory syncytial virus designed by reverse genetics. Proc Am Thorac Soc. 2005; 2 (2) 166-173
12 Collins P L, Murphy B R. Vaccines against human respiratory syncytial virus. In: Cane P A, ed. Respiratory Syncytial Virus. Amsterdam: Elsevier; 2007: 233
13 Iwane M K, Edwards K M, Szilagyi P G New Vaccine Surveillance Network et al. Population-based surveillance for hospitalizations associated with respiratory syncytial virus, influenza virus, and parainfluenza viruses among young children. Pediatrics. 2004; 113 (6) 1758-1764
14 Collins P L, Graham B S. Viral and host factors in human respiratory syncytial virus pathogenesis. J Virol. 2008; 82 (5) 2040-2055
15 Walsh E E, Schlesinger J J, Brandriss M W. Protection from respiratory syncytial virus infection in cotton rats by passive transfer of monoclonal antibodies. Infect Immun. 1984; 43 (2) 756-758
16 Johnson P R, Spriggs M K, Olmsted R A, Collins P L. The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically related proteins. Proc Natl Acad Sci U S A. 1987; 84 (16) 5625-5629
17 Collarini E J, Lee F E, Foord O et al.. Potent high-affinity antibodies for treatment and prophylaxis of respiratory syncytial virus derived from B cells of infected patients. J Immunol. 2009; 183 (10) 6338-6345
18 Haynes L M, Caidi H, Radu G U et al.. Therapeutic monoclonal antibody treatment targeting respiratory syncytial virus (RSV) G protein mediates viral clearance and reduces the pathogenesis of RSV infection in BALB/c mice. J Infect Dis. 2009; 200 (3) 439-447
19 Harcourt J, Alvarez R, Jones L P, Henderson C, Anderson L J, Tripp R A. Respiratory syncytial virus G protein and G protein CX3C motif adversely affect CX3CR1 + T cell responses. J Immunol. 2006; 176 (3) 1600-1608
20 Harcourt J L, Karron R A, Tripp R A. Anti-G protein antibody responses to respiratory syncytial virus infection or vaccination are associated with inhibition of G protein CX3C-CX3CR1 binding and leukocyte chemotaxis. J Infect Dis. 2004; 190 (11) 1936-1940
21 Sullender W M, Mufson M A, Prince G A, Anderson L J, Wertz G W. Antigenic and genetic diversity among the attachment proteins of group A respiratory syncytial viruses that have caused repeat infections in children. J Infect Dis. 1998; 178 (4) 925-932
22 Mufson M A, Belshe R B, Orvell C, Norrby E. Subgroup characteristics of respiratory syncytial virus strains recovered from children with two consecutive infections. J Clin Microbiol. 1987; 25 (8) 1535-1539
23 Hall C B, Walsh E E, Schnabel K C et al.. Occurrence of groups A and B of respiratory syncytial virus over 15 years: associated epidemiologic and clinical characteristics in hospitalized and ambulatory children. J Infect Dis. 1990; 162 (6) 1283-1290
24 McConnochie K M, Hall C B, Walsh E E, Roghmann K J. Variation in severity of respiratory syncytial virus infections with subtype. J Pediatr. 1990; 117 (1 Pt 1) 52-62
25 Hall C B, Douglas Jr R G, Schnabel K C, Geiman J M. Infectivity of respiratory syncytial virus by various routes of inoculation. Infect Immun. 1981; 33 (3) 779-783
26 Lee F E, Walsh E E, Falsey A R et al.. The balance between influenza- and RSV-specific CD4 T cells secreting IL-10 or IFNgamma in young and healthy-elderly subjects. Mech Ageing Dev. 2005; 126 (11) 1223-1229
27 Falsey A R, Treanor J J, Betts R F, Walsh E E. Viral respiratory infections in the institutionalized elderly: clinical and epidemiologic findings. J Am Geriatr Soc. 1992; 40 (2) 115-119
28 Falsey A R, Formica M A, Treanor J J, Walsh E E. Comparison of quantitative reverse transcription-PCR to viral culture for assessment of respiratory syncytial virus shedding. J Clin Microbiol. 2003; 41 (9) 4160-4165
29 Weinberg G A, Erdman D D, Edwards K M New Vaccine Surveillance Network Study Group et al. Superiority of reverse-transcription polymerase chain reaction to conventional viral culture in the diagnosis of acute respiratory tract infections in children. J Infect Dis. 2004; 189 (4) 706-710
30 Subbarao E K, Whitehurst N J, Waner J L. Comparison of two enzyme-linked immunosorbent assay (EIA) kits with immunofluorescence and isolation in cell culture for detection of respiratory syncytial virus (RSV). Diagn Microbiol Infect Dis. 1987; 8 (4) 229-234
31 Ahluwalia G S, Hammond G W. Comparison of cell culture and three enzyme-linked immunosorbent assays for the rapid diagnosis of respiratory syncytial virus from nasopharyngeal aspirate and tracheal secretion specimens. Diagn Microbiol Infect Dis. 1988; 9 (3) 187-192
32 Hall W J, Hall C B, Speers D M. Respiratory syncytial virus infection in adults: clinical, virologic, and serial pulmonary function studies. Ann Intern Med. 1978; 88 (2) 203-205
33 Duncan C B, Walsh E E, Peterson D R, Lee F E, Falsey A R. Risk factors for respiratory failure associated with respiratory syncytial virus infection in adults. J Infect Dis. 2009; 200 (8) 1242-1246
34 Falsey A R, Formica M A, Walsh E E. Diagnosis of respiratory syncytial virus infection: comparison of reverse transcription-PCR to viral culture and serology in adults with respiratory illness. J Clin Microbiol. 2002; 40 (3) 817-820
35 Englund J A, Piedra P A, Jewell A, Patel K, Baxter B B, Whimbey E. Rapid diagnosis of respiratory syncytial virus infections in immunocompromised adults. J Clin Microbiol. 1996; 34 (7) 1649-1653
36 Casiano-Colón A E, Hulbert B B, Mayer T K, Walsh E E, Falsey A R. Lack of sensitivity of rapid antigen tests for the diagnosis of respiratory syncytial virus infection in adults. J Clin Virol. 2003; 28 (2) 169-174
37 Walsh E E, Falsey A R. Age related differences in humoral immune response to respiratory syncytial virus infection in adults. J Med Virol. 2004; 73 (2) 295-299
38 Hall C B, Kopelman A E, Douglas Jr R G, Geiman J M, Meagher M P. Neonatal respiratory syncytial virus infection. N Engl J Med. 1979; 300 (8) 393-396
39 Nicholson K G, Kent J, Hammersley V, Cancio E. Acute viral infections of upper respiratory tract in elderly people living in the community: comparative, prospective, population based study of disease burden. BMJ. 1997; 315 (7115) 1060-1064
40 Nicholson K G. Impact of influenza and respiratory syncytial virus on mortality in England and Wales from January 1975 to December 1990. Epidemiol Infect. 1996; 116 (1) 51-63
41 Griffin M R, Coffey C S, Neuzil K M, Mitchel Jr E F, Wright P F, Edwards K M. Winter viruses: influenza- and respiratory syncytial virus-related morbidity in chronic lung disease. Arch Intern Med. 2002; 162 (11) 1229-1236
42 Mullooly J P, Bridges C B, Thompson W W Vaccine Safety Datalink Adult Working Group et al. Influenza- and RSV-associated hospitalizations among adults. Vaccine. 2007; 25 (5) 846-855
43 Thompson W W, Shay D K, Weintraub E et al.. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003; 289 (2) 179-186
44 Hall C B, Long C E, Schnabel K C. Respiratory syncytial virus infections in previously healthy working adults. Clin Infect Dis. 2001; 33 (6) 792-796
45 Hall W J, Hall C B, Speers D M. Respiratory syncytial virus infection in adults: clinical, virologic, and serial pulmonary function studies. Ann Intern Med. 1978; 88 (2) 203-205
46 Falsey A R, Cunningham C K, Barker W H et al.. Respiratory syncytial virus and influenza A infections in the hospitalized elderly. J Infect Dis. 1995; 172 (2) 389-394
47 Hutchinson A F, Ghimire A K, Thompson M A et al.. A community-based, time-matched, case-control study of respiratory viruses and exacerbations of COPD. Respir Med. 2007; 101 (12) 2472-2481
48 De Serres G, Lampron N, La Forge J et al.. Importance of viral and bacterial infections in chronic obstructive pulmonary disease exacerbations. J Clin Virol. 2009; 46 (2) 129-133
49 Camargo Jr C A, Ginde A A, Clark S, Cartwright C P, Falsey A R, Niewoehner D E. Viral pathogens in acute exacerbations of chronic obstructive pulmonary disease. Intern Emerg Med. 2008; 3 (4) 355-359
50 Ko F W, Ip M, Chan P K et al.. Viral etiology of acute exacerbations of COPD in Hong Kong. Chest. 2007; 132 (3) 900-908
51 Beckham J D, Cadena A, Lin J et al.. Respiratory viral infections in patients with chronic, obstructive pulmonary disease. J Infect. 2005; 50 (4) 322-330
52 Rohde G, Wiethege A, Borg I et al.. Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case-control study. Thorax. 2003; 58 (1) 37-42
53 Falsey A R, Formica M A, Hennessey P A, Criddle M M, Sullender W M, Walsh E E. Detection of respiratory syncytial virus in adults with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006; 173 (6) 639-643
54 Wilkinson T M, Donaldson G C, Johnston S L, Openshaw P J, Wedzicha J A. Respiratory syncytial virus, airway inflammation, and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006; 173 (8) 871-876
55 Sikkel M B, Quint J K, Mallia P, Wedzicha J A, Johnston S L. Respiratory syncytial virus persistence in chronic obstructive pulmonary disease. Pediatr Infect Dis J. 2008; 27 (10, Suppl) S63-S70
56 Borg I, Rohde G, Löseke S et al.. Evaluation of a quantitative real-time PCR for the detection of respiratory syncytial virus in pulmonary diseases. Eur Respir J. 2003; 21 (6) 944-951
57 Nicholson K G, McNally T, Silverman M, Simons P, Stockton J D, Zambon M C. Rates of hospitalisation for influenza, respiratory syncytial virus and human metapneumovirus among infants and young children. Vaccine. 2006; 24 (1) 102-108
58 Dowell S F, Anderson L J, Gary Jr H E et al.. Respiratory syncytial virus is an important cause of community-acquired lower respiratory infection among hospitalized adults. J Infect Dis. 1996; 174 (3) 456-462
59 Walsh E E, Peterson D R, Falsey A R. Is clinical recognition of respiratory syncytial virus infection in hospitalized elderly and high-risk adults possible?. J Infect Dis. 2007; 195 (7) 1046-1051
60 DeVincenzo J P, Wilkinson T, Vaishnaw A et al.. Viral load drives disease in humans experimentally infected with respiratory syncytial virus. Am J Respir Crit Care Med. 2010; 182 (10) 1305-1314
61 DeVincenzo J P, El Saleeby C M, Bush A J. Respiratory syncytial virus load predicts disease severity in previously healthy infants. J Infect Dis. 2005; 191 (11) 1861-1868
62 Buckingham S C, Bush A J, Devincenzo J P. Nasal quantity of respiratory syncytial virus correlates with disease severity in hospitalized infants. Pediatr Infect Dis J. 2000; 19 (2) 113-117
63 Houben M L, Coenjaerts F E, Rossen J W et al.. Disease severity and viral load are correlated in infants with primary respiratory syncytial virus infection in the community. J Med Virol. 2010; 82 (7) 1266-1271
64 Walsh E E, Peterson D R, Falsey A R. Risk factors for severe respiratory syncytial virus infection in elderly persons. J Infect Dis. 2004; 189 (2) 233-238
65 Falsey A R. Noninfluenza respiratory virus infection in long-term care facilities. Infect Control Hosp Epidemiol. 1991; 12 (10) 602-608
66 Mathur U, Bentley D W, Hall C B. Concurrent respiratory syncytial virus and influenza A infections in the institutionalized elderly and chronically ill. Ann Intern Med. 1980; 93 (1) 49-52
67 Caram L B, Chen J, Taggart E W et al.. Respiratory syncytial virus outbreak in a long-term care facility detected using reverse transcriptase polymerase chain reaction: an argument for real-time detection methods. J Am Geriatr Soc. 2009; 57 (3) 482-485
68 Drinka P J, Gravenstein S, Krause P et al.. Non-influenza respiratory viruses may overlap and obscure influenza activity. J Am Geriatr Soc. 1999; 47 (9) 1087-1093
69 Ellis S E, Coffey C S, Mitchel Jr E F, Dittus R S, Griffin M R. Influenza- and respiratory syncytial virus-associated morbidity and mortality in the nursing home population. J Am Geriatr Soc. 2003; 51 (6) 761-767
70 Falsey A R, McCann R M, Hall W J et al.. Acute respiratory tract infection in daycare centers for older persons. J Am Geriatr Soc. 1995; 43 (1) 30-36
71 Wendt C H, Hertz M I. Respiratory syncytial virus and parainfluenza virus infections in the immunocompromised host. Semin Respir Infect. 1995; 10 (4) 224-231
72 McColl M D, Corser R B, Bremner J, Chopra R. Respiratory syncytial virus infection in adult BMT recipients: effective therapy with short duration nebulised ribavirin. Bone Marrow Transplant. 1998; 21 (4) 423-425
73 Mazzulli T, Peret T C, McGeer A et al.. Molecular characterization of a nosocomial outbreak of human respiratory syncytial virus on an adult leukemia/lymphoma ward. J Infect Dis. 1999; 180 (5) 1686-1689
74 Whimbey E, Champlin R E, Couch R B et al.. Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis. 1996; 22 (5) 778-782
75 Whimbey E, Couch R B, Englund J A et al.. Respiratory syncytial virus pneumonia in hospitalized adult patients with leukemia. Clin Infect Dis. 1995; 21 (2) 376-379
76 Englund J A, Anderson L J, Rhame F S. Nosocomial transmission of respiratory syncytial virus in immunocompromised adults. J Clin Microbiol. 1991; 29 (1) 115-119
77 Hertz M I, Englund J A, Snover D, Bitterman P B, McGlave P B. Respiratory syncytial virus-induced acute lung injury in adult patients with bone marrow transplants: a clinical approach and review of the literature. Medicine (Baltimore). 1989; 68 (5) 269-281
78 Englund J A, Sullivan C J, Jordan M C, Dehner L P, Vercellotti G M, Balfour Jr H H. Respiratory syncytial virus infection in immunocompromised adults. Ann Intern Med. 1988; 109 (3) 203-208
79 Shah J N, Chemaly R F. Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. Blood. 2011; 117 (10) 2755-2763
80 Boeckh M. The challenge of respiratory virus infections in hematopoietic cell transplant recipients. Br J Haematol. 2008; 143 (4) 455-467
81 Erard V, Chien J W, Kim H W et al.. Airflow decline after myeloablative allogeneic hematopoietic cell transplantation: the role of community respiratory viruses. J Infect Dis. 2006; 193 (12) 1619-1625
82 Kim Y J, Boeckh M, Englund J A. Community respiratory virus infections in immunocompromised patients: hematopoietic stem cell and solid organ transplant recipients, and individuals with human immunodeficiency virus infection. Semin Respir Crit Care Med. 2007; 28 (2) 222-242
83 Zamora M R, Budev M, Rolfe M et al.. RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. Am J Respir Crit Care Med. 2011; 183 (4) 531-538
84 Kumar D, Erdman D, Keshavjee S et al.. Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant. Am J Transplant. 2005; 5 (8) 2031-2036
85 Glezen W P, Paredes A, Allison J E, Taber L H, Frank A L. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J Pediatr. 1981; 98 (5) 708-715
86 Carbonell-Estrany X, Simões E A, Dagan R Motavizumab Study Group et al. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics. 2010; 125 (1) e35-e51
87 IMpact-RSV Study Group . Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998; 102 (3) 531-537
88 Malley R, DeVincenzo J, Ramilo O et al.. Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J Infect Dis. 1998; 178 (6) 1555-1561
89 Lee F E, Walsh E E, Falsey A R, Betts R F, Treanor J J. Experimental infection of humans with A2 respiratory syncytial virus. Antiviral Res. 2004; 63 (3) 191-196
90 Mills J V, Van Kirk J E, Wright P F, Chanock R M. Experimental respiratory syncytial virus infection of adults: possible mechanisms of resistance to infection and illness. J Immunol. 1971; 107 (1) 123-130
91 Hall C B, Walsh E E, Long C E, Schnabel K C. Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis. 1991; 163 (4) 693-698
92 Walsh E E, Falsey A R. Humoral and mucosal immunity in protection from natural respiratory syncytial virus infection in adults. J Infect Dis. 2004; 190 (2) 373-378
93 Martinez-Sobrido L, Gitiban N, Fernandez-Sesma A et al.. Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector. J Virol. 2006; 80 (3) 1130-1139
94 Johnson T R, Mertz S E, Gitiban N et al.. Role for innate IFNs in determining respiratory syncytial virus immunopathology. J Immunol. 2005; 174 (11) 7234-7241
95 Villenave R, O'Donoghue D, Thavagnanam S et al.. Differential cytopathogenesis of respiratory syncytial virus prototypic and clinical isolates in primary pediatric bronchial epithelial cells. Virol J. 2011; 8 (1) 43
96 Thornburg N J, Shepherd B, Crowe Jr J E. Transforming growth factor beta is a major regulator of human neonatal immune responses following respiratory syncytial virus infection. J Virol. 2010; 84 (24) 12895-12902
97 Oshansky C M, Barber J P, Crabtree J, Tripp R A. Respiratory syncytial virus F and G proteins induce interleukin 1alpha, CC, and CXC chemokine responses by normal human bronchoepithelial cells. J Infect Dis. 2010; 201 (8) 1201-1207
98 Oshansky C M, Zhang W, Moore E, Tripp R A. The host response and molecular pathogenesis associated with respiratory syncytial virus infection. Future Microbiol. 2009; 4 (3) 279-297
99 Halfhide C P, Brearey S P, Flanagan B F et al.. Neutrophil TLR4 expression is reduced in the airways of infants with severe bronchiolitis. Thorax. 2009; 64 (9) 798-805
100 Lukens M V, van de Pol A C, Coenjaerts F E et al.. A systemic neutrophil response precedes robust CD8( + ) T-cell activation during natural respiratory syncytial virus infection in infants. J Virol. 2010; 84 (5) 2374-2383
101 Miyairi I, DeVincenzo J P. Human genetic factors and respiratory syncytial virus disease severity. Clin Microbiol Rev. 2008; 21 (4) 686-703
102 Janssen R, Bont L, Siezen C L et al.. Genetic susceptibility to respiratory syncytial virus bronchiolitis is predominantly associated with innate immune genes. J Infect Dis. 2007; 196 (6) 826-834
103 Kapikian A Z, Mitchell R H, Chanock R M, Shvedoff R A, Stewart C E. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol. 1969; 89 (4) 405-421
104 Lee D C, Harker J A, Tregoning J S et al.. CD25 + natural regulatory T cells are critical in limiting innate and adaptive immunity and resolving disease following respiratory syncytial virus infection. J Virol. 2010; 84 (17) 8790-8798
105 Welliver T P, Reed J L, Welliver Sr R CS. Respiratory syncytial virus and influenza virus infections: observations from tissues of fatal infant cases. Pediatr Infect Dis J. 2008; 27 (10, Suppl) S92-S96
106 Welliver T P, Garofalo R P, Hosakote Y et al.. Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses. J Infect Dis. 2007; 195 (8) 1126-1136
107 Looney R J, Falsey A R, Walsh E, Campbell D. Effect of aging on cytokine production in response to respiratory syncytial virus infection. J Infect Dis. 2002; 185 (5) 682-685
108 Groothuis J R, Woodin K A, Katz R et al.. Early ribavirin treatment of respiratory syncytial viral infection in high-risk children. J Pediatr. 1990; 117 (5) 792-798
109 Hall C B, McBride J T, Gala C L, Hildreth S W, Schnabel K C. Ribavirin treatment of respiratory syncytial viral infection in infants with underlying cardiopulmonary disease. JAMA. 1985; 254 (21) 3047-3051
110 Englund J A, Piedra P A, Jefferson L S, Wilson S Z, Taber L H, Gilbert B E. High-dose, short-duration ribavirin aerosol therapy in children with suspected respiratory syncytial virus infection. J Pediatr. 1990; 117 (2 Pt 1) 313-320
111 American Academy of Pediatrics Subcommittee on Diagnosis and Management of Bronchiolitis . Diagnosis and management of bronchiolitis. Pediatrics. 2006; 118 (4) 1774-1793
112 The PREVENT Study Group . Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics. 1997; 99 (1) 93-99
113 Zempsky W T, Schechter N L. IMpact-RSV study group report. Pediatrics. 1999; 104 (4 Pt 1) 993-994 author reply 995
114 Lee F E, Walsh E E, Falsey A R. The effect of steroid use in hospitalized adults with respiratory syncytial virus related illness. Chest. 2011 May 12. [Epub ahead of print]
115 Chemaly R F, Ghosh S, Bodey G P et al.. Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. Medicine (Baltimore). 2006; 85 (5) 278-287
116 Torres H A, Aguilera E A, Mattiuzzi G N et al.. Characteristics and outcome of respiratory syncytial virus infection in patients with leukemia. Haematologica. 2007; 92 (9) 1216-1223
117 Empey K M, Peebles Jr R S, Kolls J K. Pharmacologic advances in the treatment and prevention of respiratory syncytial virus. Clin Infect Dis. 2010; 50 (9) 1258-1267
118 Murata Y. Respiratory syncytial virus vaccine development. Clin Lab Med. 2009; 29 (4) 725-739
119 Gonzalez I M, Karron R A, Eichelberger M et al.. Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults. Vaccine. 2000; 18 (17) 1763-1772
120 Falsey A R, Walsh E E, Capellan J et al.. Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (RSV) vaccines—nonadjuvanted vaccine or vaccine adjuvanted with alum—given concomitantly with influenza vaccine to high-risk elderly individuals. J Infect Dis. 2008; 198 (9) 1317-1326
121 Falsey A R, Walsh E E. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60. Vaccine. 1996; 14 (13) 1214-1218

Edward E WalshM.D.

Department of Medicine, University of Rochester School of Medicine and Dentistry

1425 Portland Ave., Rochester, NY 14621

Email: edward.walsh@rochestergeneral.org